<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04604353</url>
  </required_header>
  <id_info>
    <org_study_id>492/20</org_study_id>
    <nct_id>NCT04604353</nct_id>
  </id_info>
  <brief_title>Early Detection of Coronary Artery Disease by Polygenic and Metabolic Risk Scoring</brief_title>
  <acronym>EDCAD-PMS</acronym>
  <official_title>Early Detection of Coronary Artery Disease by Polygenic and Metabolic Risk Scoring in at Risk Patients: Comparison With Coronary Computed Tomography</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Baker Heart and Diabetes Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Baker Heart and Diabetes Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overall goal of this study is to develop a combined polygenic risk score (PRS) and&#xD;
      metabolic risk score (MRS) and determine its impact on selecting community members for CCS.&#xD;
      The trial component of this study will compare the use of these scores to motivate people to&#xD;
      adhere to therapy, an ongoing challenge for clinicians, by providing feedback in a meaningful&#xD;
      form to both the clinicians and the patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients undergoing a polygenic risk score (PRS), metabolic risk score (MRS) and coronary&#xD;
      calcium score (CCS) will be randomized to receive PRS and CCS information and followed for&#xD;
      the reduction of risk over 12 months. This information will provide information about how to&#xD;
      motivate people to adhere to therapy, by providing feedback in a meaningful form to both the&#xD;
      clinicians and the patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 7, 2020</start_date>
  <completion_date type="Anticipated">October 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">October 30, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomization to provision of PRS-based or CCS-based risk</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>Outcomes assessor will receive baseline and 12 month risk based on Pooled Cohort Equation and photographic evidence of treatment adherence</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change in cardiovascular risk in each group</measure>
    <time_frame>12 months</time_frame>
    <description>Change in cardiovascular risk (expressed as pooled cohort equation 10-year risk percentage) from baseline to follow-up</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Medication adherence in each group</measure>
    <time_frame>12 months</time_frame>
    <description>Proportion of lipid-lowering tablets taken</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">948</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>PRS score group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Risk information provided on the basis of Polygenic Risk Score combined with the Pooled Cohort Equation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CCS score group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Risk information provided on the basis of Coronary Calcium Score combined with the Pooled Cohort Equation</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Polygenic Risk Score</intervention_name>
    <description>Risk description to patient based on PRS</description>
    <arm_group_label>PRS score group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Coronary Calcium Score</intervention_name>
    <description>Risk description to patient based on CCS</description>
    <arm_group_label>CCS score group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Asymptomatic subjects age 40-70y&#xD;
&#xD;
          2. Statin naïve&#xD;
&#xD;
          3. TC ≤ 6.5 mmol/L and LDLC &lt;5 mmol/L, and&#xD;
&#xD;
          4. 5 year Australian risk ≥2%.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Symptomatic coronary, cerebrovascular, or peripheral vascular disease&#xD;
&#xD;
          2. Intolerance of statins or currently on statins for any length of time&#xD;
&#xD;
          3. Pre-existing muscle disease (eg polymyositis, fibromyalgia) - this may be confused&#xD;
             with myalgia from statins&#xD;
&#xD;
          4. Patients on drugs that increase the risk of myopathy/rhabdomyolysis such as&#xD;
             cyclosporine and strong CYP3A4 inhibitors (e.g., clarithromycin, itraconazole, and&#xD;
             HIV/hepatitis C protease inhibitors)&#xD;
&#xD;
          5. Atrial fibrillation (interferes with CTCA)&#xD;
&#xD;
          6. Chronic kidney disease on haemodialysis (because of vascular calcification) or GFR&#xD;
             &lt;50ml/min per 1.73m2 using the Modification of Diet in Renal Disease (MDRD) formula&#xD;
&#xD;
          7. Inability to provide informed consent&#xD;
&#xD;
          8. Major systemic illness eg. malignancy; rheumatoid arthritis&#xD;
&#xD;
          9. Women of child bearing potential (due to performance of CT)&#xD;
&#xD;
         10. Poorly controlled hypertension: SBP&gt; 200 and or DBP &gt; 100&#xD;
&#xD;
         11. Severe psychiatric disorder (eg bipolar depression; psychosis)&#xD;
&#xD;
         12. Patients eligible for treatment based on current Australian guidelines (5 year risk&#xD;
             &gt;15%)&#xD;
&#xD;
         13. Patients eligible for treatment based on current PBS thresholds TC &gt;7.5 mmol/l and&#xD;
             other criteria (see below).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas H Marwick, MD, PhD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Baker Heart and Diabetes Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Carla Duarte, BS</last_name>
    <phone>+61385321550</phone>
    <email>carla.duarte@baker.edu.au</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Thomas H Marwick, MD, PhD, MPH</last_name>
    <phone>+61385321550</phone>
    <email>tom.marwick@baker.edu.au</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Baker Heart and Diabetes Institute</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Marwick</last_name>
      <phone>+61385321550</phone>
      <email>tom.marwick@baker.edu.au</email>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>October 19, 2020</study_first_submitted>
  <study_first_submitted_qc>October 24, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 27, 2020</study_first_posted>
  <last_update_submitted>January 19, 2021</last_update_submitted>
  <last_update_submitted_qc>January 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Calcium</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Data sharing based available on application to the study PI</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

